Northwest Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $253.3M
- Price
- $0.1485
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.71%
- Volume
- 3.9M
About
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Quick stats
Shares outstanding1.7B
Computed float1.6B
Float / shares95.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001072379
Websitehttps://www.nwbio.com
AI Summary
AI-generated1/6
minorneutraloperations update
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will deliver an invited keynote at the UK NHS CancerCare Oncology Conference on October 6.
The talk covers the new era of cancer vaccines and the company's DCVax platform, including clinical trial results and potential combination treatments; slides will be posted to the company website afterward.
The event is promotional rather than data-generating: the company's UK MAA for DCVax-L in glioblastoma remains under review, and no new results or regulatory milestones were announced.